BRCA2 and prostate carcinoma: Our study applied a new recommended definition of aggressive prostate cancer and provides further evidence that rare germline pathogenic variants in ATM, BRCA1, and BRCA2 are associated with increased risk of this aggressive, clinically relevant subset of prostate cancer.